Group 1 - The company *ST Shuangcheng (002693.SZ) stated on the interactive platform that there are no plans for restructuring [1]

Group 1 - The company *ST Shuangcheng (002693.SZ) has stated that it currently does not have any innovative drug research and development [1]

Core Points - The company *ST Shuangcheng (002693.SZ)* announced a restricted stock and stock option incentive plan for 2025, proposing to grant a total of 20 million stock rights, accounting for 4.82% of the company's total share capital of 414.68975 million shares at the time of the announcement [1] Group 1 - The incentive plan includes a restricted stock grant of 12 million shares, representing 2.89% of the total share capital [1] - The stock option grant proposed in the plan is 8 million shares, which is 1.93% of the total share capital [1] - The grant price for the restricted stock is set at 3.97 yuan per share, while the exercise price for the stock options is 7.93 yuan per share [1] Group 2 - A total of 149 individuals will be granted the incentives, including directors, senior management, middle management, and key technical (business) personnel, excluding independent directors and shareholders holding more than 5% of shares [1] - The validity period for the restricted stock is from the completion of the grant registration until all restrictions are lifted or the stock is repurchased, lasting no more than 48 months [2] - The validity period for the stock options is similarly set from the completion of the grant registration until all options are exercised or canceled, also lasting no more than 48 months [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD 4,000,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （ 於開曼群島註冊成立之有限公司） （股份代號︰269） 有關解決不發表意見的行動的季度更新 本公告由中國資源交通集團有限公司(「本公司」，連同其附屬公司，統稱「本 集團」)董事 (「董事」)會(「董事會」)根據香港聯合交易所有限公司(「聯交 所」)證券上市規則(「上市規則」)第13.09條及證券及期貨條例(香港法例第571 章)第 XIVA 部項下內幕消息條文(定義見上市規則)作出。 截至2025年7月31日，本公司較2025年4月30日進一步償還無擔保債務人民幣 13.81百萬元，剩餘未償還金額約為人民幣25.25百萬元，預計將於2025年9月26 日或之前全部清償。 於2025年7月11日，管理人与所有債務資本化債權人召開線上會議，就建議的債 務資本化實施方案及相關協議，以 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （ 於開曼群島註冊成立之有限公司） （股份代號︰269） 股東週年大會之投票結果 董事會欣然宣佈，所有於2025年8月28日舉行之股東週年大會上提呈之決議案已 獲正式通過 董事會欣然宣佈，該通告所載之所有決議案均已於2025年8月28日舉行之股東週 年大會上以投票表決方式獲正式通過。於股東週年大會日期，本公司已發行股份 為 10,644,093,185 股，而所有股東均有權出席大會並於會上投票贊成或反對該通 告所載所有普通及特別決議案。本公司於股東週年大會日期概無持有庫存股（包 括任何持有或存入中央結算系統的庫存股）。概無股份賦予股東權利出席股東週 年大會及須於會上放棄投票贊成任何決議案。概無股東須根據上市規則於股東週 年大會上對任何決議案放棄投票。概無股東於該通函中表明其有意對任 ...

Core Viewpoint - *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable paclitaxel (albumin-bound) product, which is now available for export sales in the United States [1] Company Summary - The company announced that its ANDA for injectable paclitaxel (100 mg/vial) has been approved by the U.S. FDA [1] - The product information will be disclosed in accordance with legal regulations, and investors are advised to refer to the company's announcements on designated media and the Giant Tide Information Network [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has recently received marketing authorization for its arginine vasopressin injection from the Australian Therapeutic Goods Administration (TGA) [1] Group 1: Company Developments - The company has obtained a significant regulatory approval for its arginine vasopressin injection, which is a critical step for market entry [1] - The product is available in a specification of 20 pressor units per 1 mL [1] Group 2: Market Insights - According to the Insight database, the global sales for arginine vasopressin injection are projected to reach approximately $72 million in 2024 [1] - The U.S. market is expected to contribute around $46 million to the total sales [1]

Core Viewpoint - China Resources Transportation (00269) reported a decline in revenue and a significant net loss for the fiscal year ending March 31, 2024, indicating financial challenges ahead [3]. Financial Performance - The company achieved a revenue of HKD 578 million, a year-on-year decrease of 2.61% [3]. - The net profit attributable to shareholders was a loss of HKD 338 million, compared to a profit of HKD 1.732 billion in the same period last year [3]. - The net cash flow from operating activities was HKD 187 million, down 82.12% year-on-year [3][18]. - The basic earnings per share stood at -HKD 0.03 [3]. Revenue Composition - The revenue composition for the fiscal year 2024-2025 shows that highway operations contributed HKD 576.9 million, while other operations contributed HKD 0.008 million [14]. Business Segments - The company operates primarily in three segments: highway operations, oil trading and services, and timber operations [8]. - The highway operations segment includes the operation, management, and maintenance of highways, along with investment in supporting facilities [8]. Cash Flow Analysis - The net cash flow from financing activities was -HKD 182 million, an increase of HKD 87.2 million year-on-year [18]. - The net cash flow from investing activities was -HKD 8.232 million, compared to -HKD 0.343 million in the previous year [18]. Asset and Liability Changes - As of March 31, 2025, prepayments increased by 139.9%, accounting for a 3.34 percentage point rise in total assets [28]. - Intangible assets decreased by 6.04%, leading to a 1.85 percentage point drop in total assets [28]. - Other payables (including interest and dividends) increased by 3.4%, contributing to a 6.41 percentage point rise in total assets [31]. Financial Ratios - The company reported a current ratio of 0.03 and a quick ratio of 0.03 during the reporting period [35].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 股東週年大會通告 茲通告中國資源交通集團有限公司（「本公司」）謹訂於 2025 年 8 月 28 日（星期四）上 午十一時正假座中國廣東省深圳市福田區金田路榮超經貿中心 2408 室舉行股東週年大會 （「股東週年大會」），藉以考慮下列決議案： 作為普通事項 A. 考慮及酌情通過下列決議案（ 考慮及酌情通過下列決議案（不論有否經修訂 不論有否經修訂 不論有否經修訂）作為普通決議案 作為普通決議案: 「動議︰ CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號︰269） 作為特別事項 1. 省覽及考慮截至 2025 年 3 月 31 日止年度之經審核財務報表及本公司董事 （「董事」）會與核數師報告書。 2. 重選段景泉先生為執行董事，以及井寶利先生與包良明先生為獨立非執行董事。 3. 授權董 ...